Authors
Latest:
Investigators Observe Differences in Toxicity for Sarcoma Due to DosingGary K. Schwartz, MD, discusses adverse events seen in patients with metastatic sarcoma participating in the Alliance A091401 trial.
Latest:
Ongoing Challenges With Trials in the Community Oncology SettingBenjamin Garmezy, MD, discusses some of the ongoing challenges or disparities seen in the community oncologist setting related to clinical trials.
Latest:
Gender-Specific AI Model Advances Understanding of Glioblastoma Progression and Treatment ResponseDistinguishing on current imaging between disease progression and pseudo progression in patients with glioblastoma is one of the most difficult clinical problems, according to Manmeet Ahluwalia, MD and Pallavi Tiwari, PhD.
Latest:
Adaptation in Oncology Practice Opens the Door to SpecializationDemands by patients, market pressures, and changing delivery models have brought to the fore the urgency to address whether subspecialization is necessary and entirely feasible.
Latest:
Key Takeaways from ASH 2023 in Myelofibrosis and AMLFollowing their review of updates from clinical trials presented at ASH 2023, the Oncology Brothers provide their key takeaways on recent data in myelofibrosis and acute myeloid leukemia.
Latest:
Navigating Unmet Needs in SR/D cGvHDDr Chao provides his insights into the ongoing complexities that clinicians face and shaping a comprehensive understanding of the areas requiring further attention and innovation in cGvHD management.
Latest:
Gynecologic Cancer Awareness Month: Progress Makes Cervical Cancer Highly Treatable, Increasingly PreventableFor Gynecologic Cancer Awareness Month, Dr. Sonal Sura discusses the recent progress in the treatment of patients with cervical cancer.
Latest:
Interpreting the Results of the ELEVATE-TN Trial for Treatment-Naive CLLNakhle Saba, MD, discusses the significance of the key findings of the ELEVATE-TN trial of acalabrutinib with or without obinutuzumab for patients with chronic lymphocytic leukemia.
Latest:
Behind the Development of the DCISionRT Test in DCISChirag Shah, MD, discusses the challenges in predicting the risk of local recurrence in patients with ductal carcinoma in situ, and what led to the DCISionRT test.
Latest:
Managing Symptoms of Diarrhea Improves Medication Adherence in Patients Treated With AbemaciclibDose escalation may be beneficial for patients starting treatment regimens with a high incidence of toxicities that may lead to abrupt patient self-discontinuation.
Latest:
Quality of Life ImpactDiscussing how various treatments for chronic GvHD impact quality of life in terms of disease response and side effects.
Latest:
Axi-Cel Demonstrates Efficacy in Non-Hodgkin Lymphoma, Including DLBCLCaron Jacobson, MD, discusses the survival and response data for axicabtagene ciloleucel from the phase 1/2 ZUMA-1 trial.
Latest:
Available Options for the Treatment of EGFR+ Lung CancerEdward B. Garon, MD, MS, provides an overview of some of the available treatment options for patients with EGFR-mutated lung cancer.
Latest:
IL-10 and CXCL10 in Urine May Predict Response to BCG Therapy in Bladder CancerFelix Guerrero-Ramos, PhD, discusses the results from an analysis of IL-10 and CXCL10 in urine as useful biomarkers of response to bacillus Calmette-Guerin in patients with bladder cancer.
Latest:
Novel Treatment Strategies in Endometrial CancerClosing out their program on endometrial carcinoma management, key opinion leaders highlight key novel therapeutic strategies in the evolving treatment landscape.
Latest:
Bladder Cancer Field Leans Towards Patient-Centered CareTracy Rose, MD, discusses the promising outlook of the current bladder cancer space.
Latest:
Pegsitacianine Informs Surgery in Peritoneal CarcinomatosisCurrently, cytoreductive surgery remains a pillar of modern treatment for peritoneal carcinomatosis.
Latest:
Deep Responses in Multiple Myeloma Seen With Bispecific AntibodyJeffrey Zonder, MD, discusses the efficacy results of a first-in-human trial of a bispecific monoclonal antibody in patients with relapsed/refractory multiple myeloma.
Latest:
Turning the Tide on Opioid Prescribing PracticesIn 2017 there was a continued increase in opioid-related deaths in the United States, with more than 60,000 lives lost. Most opioid abusers report that their opioids are acquired with their own prescription or a prescription for someone else obtained illegally. Two recent retrospective studies found that in patients undergoing surgery for early non–small cell lung cancer, perioperative opioid use was associated with decreased OS and increased risk of recurrence.
Latest:
Cabazitaxel Advances Later-Line Treatment in Metastatic CRPC SettingDuring a Targeted Oncology Case-Based Roundtable event, A. Oliver Sartor, MD, discussed the results of cabazitaxel as a later-line treatment for patients with metastatic castration-resistant prostate cancer.
Latest:
Future of Myelofibrosis TreatmentsAaron Gerds, MD, MS, shares hopes that combination therapies now in trials, along with other novel approaches further down the pipeline like monoclonal antibodies, vaccines, and cellular therapies will likely radically advance treatment over the next 5 to 10 years.
Latest:
New Options Shape the Treatment Landscape of ALLAaron Logan, MD, PhD, discusses some of the treatment options available for patients with acute lymphoblastic leukemia.
Latest:
Dr. Aaron Spitz on the Role of Telemedicine in UrologyAaron Spitz, MD, talks about the emerging uses of telemedicine in urology. Telemedicine allows medical professionals to remotely diagnose and sometimes even treat patients through a variety of technology, including smartphones and tablet devices.
Latest:
Future of Myelofibrosis TreatmentAbdulraheem Yacoub, MD, closes by sharing that the myelofibrosis treatment landscape is expected to evolve in the coming years with results to come from clinical trials investigating combination therapies, novel agents, and targeted approaches for disease progression and improving durability of response.
Latest:
Dr. Abraham Chachoua on Anti-PD-1 and Anti-PD-L1 Treatments in Lung CancerAbraham Chachoua, MD, associate professor of Oncology, NYU Langone Medical Center, talks about the present use of anti-PD-1 and anti-PD-L1 becoming the standard second-line treatment in lung cancer.
Latest:
Differentiating Between the Classes of Gastric CancerAdam Bass, MD, assistant professor of medicine, Dana-Farber Cancer Institute, discusses the differentiation between the classes of gastric cancer.
